Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

A Closer Look at IL-17 Inhibitors in Psoriasis : Episode 3

Opinion

Video

March 28, 2025

Clinical Attributes of IL-17 Inhibitors in Psoriasis

Author(s):

Christopher G. Bunick, MD, PhD,James Song, MD, FAAD

Panelists discuss how IL-17 inhibitors are biologics that target the inflammatory cytokine IL-17 pathway. They demonstrate rapid onset of action, with measurable improvement in most patients within 2 to 4 weeks and peak efficacy by 12 to 16 weeks. They achieve high rates of skin clearance in psoriasis patients and maintain efficacy with long-term use.

EP: 1.The Role of IL-17 in Psoriasis Pathogenesis

EP: 2.Mechanism of Action Differences Among IL-17 Inhibitors

Now Viewing

EP: 3.Clinical Attributes of IL-17 Inhibitors in Psoriasis

EP: 4.IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis

Video content above is prompted by the following:

What are some of the clinical attributes of IL-17 inhibitors? How quickly do they work in their onset of action, and how do they impact skin clearance?